Reviewed by Sean Lucan, MD, MPH, MS — board-certified obesity medicine physician

What is Foundayo?

If you’ve been following the conversation around GLP-1 medications (the class of drugs behind Ozempic, Wegovy, and Zepbound) you’ve probably heard that something new just landed. On April 1, 2026, the FDA approved Foundayo (orforglipron), a once-daily pill made by Eli Lilly, for weight management in adults with obesity or overweight with a related health condition.

It’s the second oral GLP-1 approved for weight loss, following Novo Nordisk’s Wegovy pill in December 2025. And it’s generating a lot of questions. This post answers them. It answers plainly, without hype, and with the nuance of a decision this personal actually deserves.

How is Foundayo (orforglipron) different from other GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1 — a hormone your body naturally produces that helps regulate appetite, blood sugar, and digestion. GLP-1 medications work by mimicking that hormone, which helps reduce hunger, slow digestion, and support sustained weight loss.

Most GLP-1 medications you’ve heard of (Wegovy, Ozempic, Zepbound, Mounjaro) are typically injections. That’s because their active ingredients are peptides, which would be broken down in the digestive tract if taken by mouth.These medications are often taken weekly because they’re designed to remain active in the body for an extended period. Their long half-life, engineered through specific molecular modifications, allows for once-weekly dosing.

Foundayo is different at the molecular level. It’s a small-molecule, non-peptide GLP-1 receptor agonist. Unlike traditional GLP-1 medications, its structure allows it to be absorbed through the digestive tract, which makes it possible to take as a daily pill. That’s why it can be swallowed as a daily pill without any food or water restrictions. This ability was something that wasn’t possible with the injectable drug reformulated into pill form. In comparison, the Wegovy pill must be taken 30 minutes before consuming any food or drink to prevent interference with its absorption.

How much weight loss does Foundayo produce?

In the ATTAIN-1 clinical trial, adults taking orforglipron lost an average of 27 pounds on the highest dose. That’s an average of about 12.4% of body weight over 72 weeks (roughly a year and a half).

For context, here’s how Foundayo compares to other GLP-1 options currently available:

• Foundayo (orforglipron pill): ~12% body weight loss
• Wegovy pill (oral semaglutide): ~15% body weight loss
• Wegovy injection: ~15% body weight loss
• Zepbound injection (tirzepatide): ~20% body weight loss

What those numbers don’t capture is the difference between a medication and a care plan. Patients in Accomplish Health’s physician-led program receive GLP-1 prescriptions with ongoing clinical oversight. They also get registered dietitian support and connected monitoring. Patients achieve an average 21% body weight loss at 12 months. The medication opens the door; the care model determines what happens next.

→ Check if you’re covered and get started

A few important caveats about these numbers. None of these drugs have been tested head-to-head. Comparisons are based on separate trials with different populations and study designs. 

Real-world results also depend heavily on adherence, which is where clinical support makes an enormous difference. A drug that’s easier to take (like a pill with no fasting requirement) may outperform its trial results simply because more people stay on it.

The other thing worth understanding is what 12% actually means in a person’s life. For someone starting at 240 pounds, that’s roughly 29 pounds. In clinical research, many meaningful health improvements are seen with around 10% weight loss. At that level, people often experience reductions in blood pressure, improvements in metabolic health, and meaningful changes in conditions like sleep apnea.

That’s what makes results in this range so significant. It’s not just about appearance. It’s about changes that affect how people feel and function every day.

Who qualifies for Foundayo?

Foundayo is approved for use in adults with obesity or adults who carry excess weight in the presence of at least one weight-related comorbid condition. 

 In practical terms, that means:

• A BMI of 30 or higher, or
• A BMI of 27 or higher with a related health condition (such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea)
• Foundayo is approved for adults only. Its safety and efficacy haven’t been established in children. 

A licensed healthcare provider needs to evaluate your health history and determine whether Foundayo is appropriate for you. It cannot be combined with another GLP-1 medication. And people taking birth control pills should talk with their doctors about potentially starting another prevention method, as birth control pills may not work as well while taking Foundayo. 

What does Foundayo cost?

This is where many people’s questions get complicated fast. Here’s the clearest breakdown available right now:

• Commercial insurance: Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card. Whether your specific plan covers it depends on your insurer and formulary. Coverage policies for this brand-new drug are still forming.
• Self-pay (no insurance): Starting doses begin at $149 per month. Higher doses range up to $349 per month, slightly more expensive than the Wegovy pill at its highest self-pay dose ($299), though comparable to Zepbound’s self-pay starting price of $299 per month.
• Medicare: As part of an agreement with the Trump administration, Medicare will cover the pill for some patients, with a monthly copay of no more than $50, starting as soon as July 1, 2026. 
• Medicaid: Coverage timing is still being determined and will vary by state. The BALANCE Model, a federal program expanding GLP-1 coverage for Medicaid patients, is expected to begin rolling out in May 2026.

One thing worth knowing: over-the-counter access is not possible. Foundayo is a prescription medication that requires a physician evaluation. If you see any platform offering it without a clinical consultation, that’s a red flag.

 

Foundayo vs. Wegovy pill vs. Zepbound: a plain-language comparison

You’re going to see a lot of content comparing these medications. Here’s what matters most for someone trying to figure out their options:

If you want to avoid injections entirely: Both Foundayo and the Wegovy pill are options. Foundayo has the edge in convenience. It requires no fasting, no timing requirement, and no food restrictions. The Wegovy pill produces slightly more weight loss on average but requires a stricter morning routine.

If maximum weight loss is your priority: The injectable medications, particularly Zepbound, still produce the highest average results in clinical trials. Choose Zepbound if maximum weight loss is your priority; choose Foundayo if you prefer a daily pill over injections, have needle anxiety, or want to avoid refrigeration requirements.

If cost is the deciding factor: both Foundayo and the Wegovy pill start at the same cash price of $149 per month at the lowest dose. At higher doses, oral Wegovy rises to $299 per month while Foundayo reaches up to $349 per month, making the Wegovy pill modestly cheaper at the top end, not Foundayo. For comparison, injectable Zepbound is available through Lilly’s self-pay program starting at $299 per month, putting it in the same ballpark as the pills at maintenance doses. The biggest cost variable for any of these medications is your insurance coverage, which can change the math dramatically.

If you’re considering a transition from an injectable: Lilly tested what happens when people who’ve lost weight with an injectable switch to Foundayo, finding that it helped with weight maintenance. People who switched from injectable Wegovy regained an average of 2 pounds; those who switched from Zepbound, which produced greater weight loss, regained an average of 11 pounds. 

That gap is worth discussing with your physician before making any changes.

What are the side effects?

Foundayo’s side effect profile is similar to other GLP-1 medications. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, and hair loss. 

The labeling for Foundayo includes a boxed warning for thyroid C-cell tumors. Foundayo should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2. 

Additional warnings include pancreatitis, acute kidney injury, and gallbladder disease — all consistent with the broader GLP-1 drug class.

Side effects are typically most noticeable when doses increase, and many people find they improve over time. This is one of many reasons ongoing medical supervision matters. A physician who knows your history can adjust your dose. They can suggest ways to manage symptoms. They can make informed decisions if your medication needs to change.

The thing that doesn’t change no matter which medication you’re on:

Here’s what the news cycle around Foundayo tends to skip over: the medication is one part of a larger picture.

A 2026 study published in BMJ Medicine found that stopping GLP-1 medications for as little as six months raised the risk of major cardiovascular events. Additionally, it showed that benefits built over years of continuous use can be undone in roughly half that time. The study, which followed more than 333,000 veterans with type 2 diabetes, found that two years off treatment increased cardiovascular risk by up to 22%. We broke down this study (and more) here.

The medications work when people stay on them, and people stay on them when they have a care team helping them navigate the experience. Success rates soar when patients work with qualified clinicians to adjust doses, help manage side effects, and build the nutrition and lifestyle habits that create durable change.

That’s not specific to Foundayo. It’s true of Wegovy, Zepbound, and every GLP-1 medication available today. The drug opens the door. What happens after that depends on the support around it.

Does this apply to me?

The first step isn’t choosing a medication. It’s having a conversation with a physician who specializes in obesity medicine. This should be someone who can look at your full health picture, your insurance coverage, your daily routine, and your goals, and help you figure out what actually makes sense.

At Accomplish Health, our board-certified obesity medicine physicians do exactly that. We’re in-network with most major insurance plans (including Aetna, BCBS, Cigna, Humana, Medicare, and Medicaid) and first appointments are typically available within two weeks.

Check My Eligibility

Frequently Asked Questions

 

Is Foundayo the same as Zepbound? 

No. Both are made by Eli Lilly, but they’re entirely different medications. Zepbound (tirzepatide) is a weekly injection that targets two receptors (GLP-1 and GIP) and produces higher average weight loss. Foundayo (orforglipron) is a daily pill that targets GLP-1 only and produces about 12% average body weight loss. Different drug, different mechanism, different results.

Can I get Foundayo without seeing a doctor? 

No. Foundayo requires a prescription from a licensed healthcare provider who has evaluated your medical history and determined it’s appropriate for you.

Does Foundayo work without diet and exercise? 

Clinical trials studied Foundayo in combination with a reduced-calorie diet and increased physical activity. That combination context is how it was approved and studied. Medications work best as part of a comprehensive plan.

What is metabolic whiplash? 

Metabolic whiplash is a term coined by Dr. Ziyad Al-Aly at Washington University School of Medicine to describe what happens when people stop GLP-1 medications — cardiovascular and metabolic benefits built over years can be reversed in roughly half the time. The research underscores why ongoing medical support matters for people on long-term GLP-1 therapy.

Will my insurance cover Foundayo? 

It depends on your plan. Commercial insurance policies for this newly approved drug are still forming. Eligible patients may pay as little as $25/month with a Lilly savings card. Medicare coverage begins July 1, 2026 at up to $50/month for eligible Part D beneficiaries. The best way to find out is to speak with a provider who can check your specific coverage — Accomplish Health does this as part of every initial consultation.

What is Foundayo, and how is it different from other GLP-1 medications?

Foundayo (orforglipron) is a small-molecule, non-peptide GLP-1 receptor agonist that can be taken as a daily pill, unlike traditional injectable GLP-1 medications. It is designed for more efficient absorption through the digestive tract and does not require fasting or specific timing, offering greater convenience.

How much weight loss does Foundayo produce?

In clinical trials, adults taking the highest dose of Foundayo lost an average of about 27 pounds, which is approximately 12.4% of their body weight over 72 weeks. This level of weight loss can significantly improve health conditions like sleep apnea and blood pressure.

Who qualifies for Foundayo?

Foundayo is approved for adults with obesity or overweight with at least one related health condition, such as high blood pressure, diabetes, high cholesterol, or sleep apnea. It is not approved for children and requires a healthcare provider’s evaluation.

What does Foundayo cost?

The cost varies depending on insurance and payment method. Eligible people with commercial insurance may pay as little as $25 a month with a savings card. Without insurance, doses start at $149 a month and can go up to $349. Medicare may cover it with a copay of up to $50 starting July 1, 2026, while coverage under Medicaid is still being determined.

 

Have questions about your care plan or GLP-1 medications? Reach your Accomplish Health care team at support@accomplish.health or schedule a visit.

 

This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. GLP-1 medications are FDA-approved for specific indications and must be prescribed and monitored by a licensed healthcare provider. Individual outcomes vary. Clinical data referenced reflects published studies and may not represent typical patient results.